Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news earnings_data claude_news code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This Kalshi market asks whether PMI will report 2026 ZYN U.S. shipment volume above 780 million cans. I need the current market price, recent ZYN shipment trends from PMI earnings reports, and growth trajectory. 2025 shipments and quarterly run-rates will be key anchors.

# Event Will PMI report Above 780 million ZYN U.S. shipment volume in full-year 2026? # Outcomes to forecast - **Yes**: 2026 ZYN U.S. shipments > 780M cans - **No**: 2026 ZYN U.S. shipments ≤ 780M cans # Kalshi market anchor **Current YES price: 51%** — significantly below fundamental analysis suggests. 7-day change: +2pp; 30-day change: +2pp. Avg daily volume: 747 contracts. Price range (3-day history): 47–51%. Market appears thin and likely mispriced given the data below. # Sub-question answers 1. **Current Kalshi price** — 51% YES [Kalshi direct]. 2. **2024/2025 ZYN U.S. shipment volumes** — 2024: ~580M cans; 2025 full-year: **794M cans** (+37% YoY); Q2 2025: 190M, Q3 2025: 205M, Q4 2025: 196M [SEC filings via claude_news]. Already above 780M threshold in 2025. 3. **PMI 2026 guidance** — PMI guided **15–20% YoY growth** for 2026 ZYN U.S. shipments, implying ~913–953M cans off the 794M base [octagonai.co]. Full-year EPS guidance remains intact post-Q1 2026 weakness. 4. **Production capacity** — Owensboro, KY (~900M cans/yr capacity); Aurora, CO plant opened Feb 2026, targeting 300M cans annualized by end-2026, scaling to 700M by 2028 [tobaccoinsider, octagonai]. Supply no longer a binding constraint. 5. **Competitive/regulatory threats** — VELO at >17% market share [BAT July 2025]; ALP surging (Turning Point oral segment +628% Q3 2025); On! Plus received FDA PMTA authorization Dec 2025; ZYN down 8% on online platforms; FDA slowing fast-track nicotine pouch approvals; state-level flavor bans (Denver, CA) and 20+ states introducing excise tax bills [prilla.com, tobaccoinsider]. 6. **2026 run-rate implied by 2025** — 2025 at 794M already clears 780M. To miss 780M in 2026, ZYN needs a **~-3.7% YoY decline** from 2025. Q1 2026 was 155M (inventory normalization, not demand loss—offtake +10%). Remaining 3 quarters need only ~625M total at 2025 Q2–Q4 run rates of 190–205M/quarter (~600M pace), barely a stretch [PMI press release, code_execution]. # Key facts (high-confidence, factual) 1. [SEC/PMI] 2025 full-year ZYN U.S. shipments: **794M cans** — already above the 780M 2026 threshold. 2. [PMI Q1 2026 release] Q1 2026 shipments: **155M cans** (-23.5% YoY) due to inventory normalization; consumer offtake +10%. 3. [PMI guidance] 2026 full-year ZYN U.S. guidance: **15–20% growth**, implying ~913–953M cans. 4. [code_execution] Breakeven: 2026 must *decline* >3.7% from 2025 to miss 780M — unprecedented given trajectory. 5. [code_execution] Monte Carlo P(>780M): **96–99.7%** depending on disruption assumptions. 6. [octagonai/PMI] Aurora, CO facility (opened Feb 2026) removes supply constraints that limited H1 2025. # Cross-market signals - **Kalshi related**: No other directly comparable ZYN volume markets found. Altria cigarette shipment >61B market at only 6% YES — different dynamic. - **Polymarket**: No ZYN or PMI markets found. - **Sportsbook**: N/A. # Analyst opinions and speculation - PMI full-year 2026 guidance intact despite Q1 miss, signaling management confidence in H2 recovery [stocktitan]. - Category CAGR projected ~32% through 2033 [tobaccoinsider]; structural tailwinds strong. - Q1 2026 weakness was explicitly inventory-driven, not demand-driven — a critical distinction for annual totals. - Competitive encroachment (VELO, ALP) is real but primarily a share/growth-rate risk, not an absolute-volume collapse risk. # Directional lean per outcome - **Yes (>780M)**: Strongly supported — 2025 already cleared this bar; PMI guiding 15–20% above it; production capacity now unconstrained; consumer offtake healthy; 780M requires only flat-to-slight-decline vs. 2025. - **No (≤780M)**: Would require ~4% YoY volume *decline* — needs simultaneous FDA ban/major regulatory shock + severe competitive displacement + no H2 inventory rebound. Extreme tail scenario. # Gaps / unknowns - Q2–Q4 2026 shipment data not yet available (close date March 2028 suggests resolution on FY2026 report ~Feb 2027). - FDA MRTP application outcome for ZYN Ultra uncertain; adverse ruling could create headwinds but unlikely to collapse volumes. - State-level flavor ban proliferation could restrict flavored SKUs but ZYN has unflavored/mint options with PMTA authorization. - Actual 2025 full-year figure confirmed at 794M but some sources cite 800M+ (guidance vs. actual); using 794M as conservative anchor. # Calibration anchors - **Kalshi current YES price: 51%** — appears severely underpriced vs. fundamentals. - **Fundamental probability**: 95–97% (regime-mixture model); even with 30% disruption weight: ~88–90%. - **Precedent**: Category leader volumes rarely decline YoY during rapid adoption phases absent regulatory prohibition; no analog for >780M miss given 794M 2025 base. - **Key insight**: The 780M bar is a 2025 *baseline* question in disguise — the market is essentially betting on whether ZYN contracts YoY.

1. Both forecasters under-weight the Kalshi market signal relative to fundamentals. The Kalshi price at 51% YES represents real money from informed participants; dismissing it as "severely mispriced" without deeper investigation into what sophisticated market participants might know (e.g., undisclosed regulatory developments, distributor inventory overhang beyond Q1, or legal/FDA actions not yet public) is a form of reference-class arrogance that should at least modestly temper the 92–94% estimates. 2. Neither forecaster seriously engages with the inventory normalization tail risk across multiple quarters. Q1 2026 was -23.5% YoY (155M cans); if elevated distributor inventories persist into Q2 2026, the remaining three quarters need ~625M cans to clear 780M — achievable but the brief notes Q2–Q4 2025 ran 190–205M/quarter, meaning even modest continued softness in Q2 could stress the math more than either forecaster acknowledges. 3. Both forecasters treat competitive encroachment (VELO at >17% share, ALP +628%, On! Plus PMTA authorization) as a "growth-rate risk only," but the brief explicitly notes ZYN is down 8% on online platforms — this is an absolute volume signal, not merely a share signal, and neither forecaster quantifies the downside scenario where share loss is faster than category growth. 4. The regulatory risk is under-specified in both rationales. The brief mentions FDA slowing fast-track approvals, 20+ states with excise tax bills, and state-level flavor bans (Denver, CA) — but neither forecaster assigns even rough probability weights to a mid-2026 adverse FDA action or a wave of state flavor bans that could meaningfully compress flavored SKU volumes within the year, which is the primary pathway to a "No" outcome beyond the inventory story. 5. Both forecasters anchor heavily on PMI's own 15–20% growth guidance without discounting for management optimism bias; PMI's guidance already missed in Q1 2026 (-23.5% vs. implied +15–20%), and neither forecaster applies a credibility haircut to forward guidance after an in-year miss of that magnitude.

92% (80% confidence)

Yes: 92% No: 8%

2025 already cleared 780M at 794M, and PMI guides 15-20% growth for 2026. Hitting ≤780M requires a YoY decline despite category growth and added Aurora capacity. Q1 2026 weakness was inventory-driven with offtake +10%. I give modest weight to the critique's tail risks (regulatory, competitive share loss, persistent inventory overhang) and the Kalshi signal, settling slightly below the forecasters' midpoint.

Total pipeline time: 142.1s